The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.
|Number of pages||3|
|Journal||Australian and New Zealand Journal of Medicine|
|Publication status||Published - Dec 1993|